So, should you buy or sell Altria stock after the recent decline? Before addressing this, if you are looking for an upside ...

Altria (MO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Altria has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.

Altria Group, Inc. (NYSE: MO) stock is off to a strong start in 2026, up more than 7.3%. However, MO stock was down nearly 3% ...

Altria Group's latest financial report for the final quarter of 2025 presents a complex narrative for shareholders. While ...

Discover why Altria is still a buy: 6.8% dividend, discounted valuation, FDA-approved nicotine pouches, and $85.40 bull ...

Altria Group has released its 2025 financial results, reaffirming its long-standing commitment to shareholder returns even as the company navigates the complexi ...

Altria (MO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Altria Group, Inc. MO is slated to report its second-quarter 2025 earnings on July 30, before market open. The Zacks Consensus Estimate for second-quarter revenues stands at $5.2 billion, indicating a ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

When measured against leading competitors, Philip Morris International Inc. (PM), Turning Point Brands, Inc. (TPB), and British American Tobacco p.l.c. (BTI), Altria’s relative undervaluation becomes ...

Altria remains a compelling buy due to undervaluation based on updated dividend discount models, with fair value estimates significantly above the current price. The company’s strong dividend history, ...